Eltrombopag-induced cerebral venous sinus thrombosis

Swetha Reba Mathews; Tintu Thomas; S. Harikrishnan; R. S. Jacob Jesurun

doi:10.4103/njpt.njpt_40_25

May 1, 2025National Journal of Pharmacology and Therapeutics

Eltrombopag-induced cerebral venous sinus thrombosis

View Full Paper

Ask AI

Bookmark

Share

Key Points

Cerebral venous sinus thrombosis occurred in a patient taking eltrombopag for ITP, indicating possible safety concerns.
The report discusses a 32-year-old female's case, revealing rare adverse reactions linked to a common treatment for ITP.
Following current ADR guidelines, the evaluation of eltrombopag reveals significant implications for its safe use in ITP.
Monitoring for cerebral venous sinus thrombosis is crucial in patients prescribed eltrombopag, especially those with ITP.

Implication

Case report reveals eltrombopag may cause cerebral venous sinus thrombosis in ITP patients, highlighting potential ADR risks.

Abstract

Eltrombopag is a thrombopoietin receptor agonist (TPO-RA), used for treating immune thrombocytopenic purpura (ITP). Cerebral venous sinus thrombosis (CVST) is a rare adverse drug reaction (ADR) of eltrombopag. This report highlights a case of eltrombopag-induced CVST in a 32-year-old female with ITP and endeavors to evaluate the ADR based on current guidelines of prescription of TPO-RAs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mathews et al. (2025) studied this question.

synapsesocial.com/papers/68d9051441e1c178a14f4b32 https://doi.org/10.4103/njpt.njpt_40_25

View Full Paper

Ask AI

Bookmark

Share

Eltrombopag-induced cerebral venous sinus thrombosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Eltrombopag-induced cerebral venous sinus thrombosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading